NASDAQ: CTMXCytomx Therapeutics Inc Stock
$0.87-0.07 (-7.45%)
Updated Feb 6, 2025
CTMX Price
$0.87
Fair Value Price
N/A
Market Cap
$68.09M
52 Week Low
$0.79
52 Week High
$5.85
P/E
5.12x
P/B
-2.9x
P/S
0.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$126.62M
Earnings
$13.83M
Gross Margin
100%
Operating Margin
11.89%
Profit Margin
10.9%
Debt to Equity
-6.93
Operating Cash Flow
-$88M
Beta
1.19
Next Earnings
Mar 10, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CTMX Overview
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTMX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
F
Momentum
B
Sentiment
F
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CTMX
Ranked#139 of 560
Ranked#139 of 560
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $24.39 | A | |
| $5.69 | A | |
| $68.04 | A |
Be the first to know about important CTMX news, forecast changes, insider trades & much more!
CTMX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTMX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTMX is good value based on its earnings relative to its share price (5.12x), compared to the US market average (31.69x)
P/E vs Market Valuation
CTMX is good value based on its earnings relative to its share price (5.12x), compared to the US Biotechnology industry average (-152.12x)
P/E vs Industry Valuation
CTMX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CTMX due diligence checks available for Premium users.
Valuation
CTMX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.12x
Industry
-152.12x
Market
31.69x
CTMX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CTMX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CTMX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.9x
Industry
5.03x
CTMX's financial health
Profit margin
Revenue
$33.4M
Net Income
$5.7M
Profit Margin
17.2%
CTMX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CTMX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$139.0M
Liabilities
$162.4M
Debt to equity
-6.93
CTMX's short-term assets ($124.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTMX's short-term assets ($124.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTMX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTMX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.7M
Investing
$18.2M
Financing
$0.0
CTMX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTMX vs Biotech Stocks
Cytomx Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.